

Ravit Geva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4971741/publications.pdf>

Version: 2024-02-01

94
papers

8,168
citations

218677
26
h-index

82547
72
g-index

96
all docs

96
docs citations

96
times ranked

11221
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-Class Anti-immunoglobulinâ€“like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 57-70.	7.0	30
2	Oncologic patientsâ€™™ misconceptions may impede enrollment into clinical trials: a cross-sectional study. <i>BMC Medical Research Methodology</i> , 2022, 22, 5.	3.1	5
3	Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 110-110.	1.6	0
4	Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome. <i>Current Medical Research and Opinion</i> , 2022, 38, 579-586.	1.9	0
5	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. <i>Cancer Discovery</i> , 2022, 12, 1248-1265.	9.4	36
6	Abstract CT129: A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors. <i>Cancer Research</i> , 2022, 82, CT129-CT129.	0.9	0
7	Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACS2, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20609-e20609.	1.6	3
8	Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. <i>Clinical Research in Cardiology</i> , 2021, 110, 50-60.	3.3	20
9	Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199020.	3.2	19
10	Rapid Implementation of Telemedicine During the COVID-19 Pandemic: Perspectives and Preferences of Patients with Cancer. <i>Oncologist</i> , 2021, 26, e679-e685.	3.7	75
11	Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15579-e15579.	1.6	1
12	Verification of statistical oncological endpoints on encrypted data: Confirming the feasibility of real-world data sharing without the need to reveal protected patient information.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18725-e18725.	1.6	1
13	Comparing implementation of Telemedicine compliance and feasibility among oncology patients across countries during the COVID 19 pandemic.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13622-e13622.	1.6	0
14	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	7.0	37
15	Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC). <i>Cancer Research</i> , 2021, 81, CT177-CT177.	0.9	2
16	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
17	Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	3
18	Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. <i>Nutrients</i> , 2021, 13, 4295.	4.1	11

#	ARTICLE	IF	CITATIONS
19	ASO Visual Abstract: Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases Are Associated with Systemic Recurrence. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	1
20	539...Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36l ³ , for intratumoral (ITu) injection +/- durvalumab in advanced solid tumors and lymphoma. , 2021, 9, A569-A569.		14
21	Resection Versus Observation of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1366-1374.	1.7	26
22	Prognostic significance of pancreatic fistula and postoperative complications after pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2020, 18, 24-30.	1.8	7
23	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	1.6	1,740
24	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020, 38, 11-19.	1.6	623
25	First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. <i>Cancer</i> , 2020, 126, 4926-4935.	4.1	46
26	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVD). <i>European Journal of Cancer</i> , 2020, 137, 272-284.	2.8	86
27	Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2020, 38, 1411-1420.	2.6	14
28	Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3963-3970.	1.5	55
29	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	30.7	297
30	412...First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1-4BB (GEN1046) in patients with advanced solid tumors. , 2020, , .		5
31	A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36l ³ , for intratumoral (ITu) injection alone and in combination with durvalumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3092-3092.	1.6	39
32	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3094-3094.	1.6	5
33	Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4032-4032.	1.6	10
34	A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4672-TPS4672.	1.6	29
35	A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3160-TPS3160.	1.6	1
36	Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis. <i>Transplantation Proceedings</i> , 2019, 51, 1867-1873.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. <i>Future Oncology</i> , 2019, 15, 2723-2731.	2.4	29
38	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	5.3	181
39	Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location. <i>Oncologist</i> , 2019, 24, e696-e701.	3.7	6
40	Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. <i>Supportive Care in Cancer</i> , 2019, 27, 3027-3033.	2.2	8
41	Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1092-1101.	6.4	13
42	A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2527-2527.	1.6	8
43	Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2528-2528.	1.6	23
44	Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4009-4009.	1.6	14
45	An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 140-140.	1.6	37
46	Data from an integrated cancer prevention center screening for multiple cancer types.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13069-e13069.	1.6	2
47	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	7.1	1,350
48	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
49	Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1619-1623.	1.0	82
50	LY2495655, an antityrosinase antibody, in pancreatic cancer: a randomized, phase 2 trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 871-879.	7.3	80
51	Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. <i>Cancer Biology and Therapy</i> , 2018, 19, 871-874.	3.4	18
52	First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3029-3029.	1.6	13
53	KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3514-3514.	1.6	63
54	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. <i>Journal of Clinical Oncology</i> , 2018, 36, 88-88.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Current Status of mCRC in East Europe and Middle East.. Journal of Clinical Oncology, 2018, 36, 853-853.	1.6	0
56	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. Journal of Clinical Oncology, 2018, 36, 276-276.	1.6	1
57	Ten year mortality trends among Israeli pancreatic ductal adenocarcinoma (PDAC) patients.. Journal of Clinical Oncology, 2018, 36, e16222-e16222.	1.6	0
58	Life expectancy and early detection of neoplasia: One stop screening for multiple cancer typesâ€™ 11 year (2006-2017) experience of an integrated cancer prevention center (ICPC).. Journal of Clinical Oncology, 2018, 36, e13553-e13553.	1.6	0
59	Surgical Treatment of Hepatocellular Carcinoma with a Tumor Thrombus Extending into the Right Atrium. Israel Medical Association Journal, 2018, 20, 590-591.	0.1	2
60	Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer. Integrative Cancer Therapies, 2017, 16, 258-262.	2.0	29
61	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. Journal of Clinical Oncology, 2017, 35, 3071-3071.	1.6	107
62	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. Journal of Clinical Oncology, 2017, 35, 4012-4012.	1.6	55
63	Sidedness matters: Surrogate biomarkers prognosticate colorectal cancer upon anatomic location.. Journal of Clinical Oncology, 2017, 35, 523-523.	1.6	1
64	Ten year experience of an integrated cancer prevention center screening for multiple cancer types.. Journal of Clinical Oncology, 2017, 35, 1549-1549.	1.6	0
65	Oncologic patients attitudes and participation in clinical trials.. Journal of Clinical Oncology, 2017, 35, e18029-e18029.	1.6	0
66	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 2016, 34, 2460-2467.	1.6	1,185
67	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology, The, 2016, 17, 717-726.	10.7	943
68	Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. Value in Health, 2016, 19, 82-87.	0.3	16
69	RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic <i>BRCA</i> mutation.. Journal of Clinical Oncology, 2016, 34, 4110-4110.	1.6	26
70	Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology, 2016, 34, 6010-6010.	1.6	25
71	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. Journal of Clinical Oncology, 2016, 34, 6012-6012.	1.6	33
72	KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS3631-TPS3631.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Safety and activity of topical 4% doxycycline foam (FDX104) in epidermal growth factor receptor inhibitor (EGFRI) induced skin toxicity.. Journal of Clinical Oncology, 2016, 34, 10130-10130.	1.6	0
74	CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome. PLoS ONE, 2015, 10, e0134469.	2.5	5
75	Predictive Levels of CD24 in Peripheral Blood Leukocytes for the Early Detection of Colorectal Adenomas and Adenocarcinomas. Disease Markers, 2015, 2015, 1-9.	1.3	10
76	Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International, 2015, 2015, 1-9.	1.9	6
77	Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique for BRCA1/2 mutation carriers. Psycho-Oncology, 2015, 24, 726-731.	2.3	9
78	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut, 2015, 64, 921-928.	12.1	22
79	“The Role of Primary Tumor Resection (PTR) in Metastatic Colorectal Cancer”, Current Colorectal Cancer Reports, 2015, 11, 225-230.	0.5	0
80	Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).. Journal of Clinical Oncology, 2015, 33, 3026-3026.	1.6	16
81	Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.. Journal of Clinical Oncology, 2015, 33, 4001-4001.	1.6	28
82	Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.. Journal of Clinical Oncology, 2015, 33, 3-3.	1.6	58
83	Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy?. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1489-1494.	2.5	32
84	A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3119-TPS3119.	1.6	0
85	Next-generation sequencing (NGS) in metastatic colorectal cancer (CRC) patients (pts) in Israel.. Journal of Clinical Oncology, 2014, 32, e14548-e14548.	1.6	0
86	A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.. Journal of Clinical Oncology, 2014, 32, TPS4161-TPS4161.	1.6	2
87	The Optimal Staging of Rectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 24-30.	0.5	0
88	Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. OncoTargets and Therapy, 2013, 6, 53.	2.0	13
89	Molecular profiling (MP)-selected therapy for the treatment of patients with advanced pancreaticobiliary cancer (PBC).. Journal of Clinical Oncology, 2013, 31, 195-195.	1.6	0
90	APC I1307K polymorphism as a predictive factor for colorectal neoplasia recurrence.. Journal of Clinical Oncology, 2013, 31, 1526-1526.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The Clalit Health Services experience.. Journal of Clinical Oncology, 2013, 31, e22111-e22111.	1.6	0
92	The APC I1307K polymorphism as a significant risk factor for CRC in average-risk Ashkenazi Jews.. Journal of Clinical Oncology, 2012, 30, 1507-1507.	1.6	0
93	MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, e21018-e21018.	1.6	0
94	The Co-occurrence of Breast Cancer and Soft Tissue Sarcoma in a Single Cohort Series. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 34-37.	1.3	4